Noxopharm Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: 2.404x

Noxopharm Ltd cash flow conversion efficiency. Based on the latest financial reports, Noxopharm Ltd (NOX) has a cash flow conversion efficiency ratio of 2.404x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.71 Million ≈ $-1.92 Million USD) by net assets (AU$-1.13 Million ≈ $-797.75K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Noxopharm Ltd (2016–2025)

Cash flow conversion efficiency of Noxopharm Ltd from 2016 to 2025. This chart illustrates how Noxopharm Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Noxopharm Ltd share price for real-time trading data and today's change.

Noxopharm Ltd Cash Flow Conversion Ratio Explained

Noxopharm Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Noxopharm Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Noxopharm Ltd ranked by their cash flow conversion efficiency. Also see Noxopharm Ltd (NOX) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
WISDOM ED.INTL.HLD.HD-01 F:5Q4	N/A
NGS Group AB (publ) ST:NGS	0.030x
PowerBank Corporation NEO:PBK	0.079x
NGX Ltd AU:NGX	-0.141x
Elcora Advanced Materials Corp V:ERA	0.437x
SWS Capital Bhd KLSE:7186	0.005x
BARRAMUNDI GROUP PTE. LTD F:95Z	N/A
Educational Development Corporation NASDAQ:EDUC	0.014x

Annual Cash Flow Conversion Efficiency for Noxopharm Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Noxopharm Ltd from 2016 to 2025. Review Noxopharm Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$689.96K ≈ $488.19K	AU$-5.82 Million ≈ $-4.12 Million	-8.442x	-6679.01%
2024-06-30	AU$5.50 Million ≈ $3.89 Million	AU$-684.31K ≈ $-484.19K	-0.125x	+89.68%
2023-06-30	AU$9.07 Million ≈ $6.42 Million	AU$-10.95 Million ≈ $-7.75 Million	-1.206x	-111.87%
2022-06-30	AU$24.12 Million ≈ $17.06 Million	AU$-13.73 Million ≈ $-9.72 Million	-0.569x	-162.35%
2021-06-30	AU$40.78 Million ≈ $28.85 Million	AU$-8.85 Million ≈ $-6.26 Million	-0.217x	+74.91%
2020-06-30	AU$12.87 Million ≈ $9.11 Million	AU$-11.14 Million ≈ $-7.88 Million	-0.865x	-112.84%
2019-06-30	AU$-1.45 Million ≈ $-1.03 Million	AU$-9.78 Million ≈ $-6.92 Million	6.740x	+853.61%
2018-06-30	AU$10.15 Million ≈ $7.18 Million	AU$-9.08 Million ≈ $-6.42 Million	-0.894x	+24.37%
2017-06-30	AU$2.47 Million ≈ $1.75 Million	AU$-2.92 Million ≈ $-2.06 Million	-1.183x	-1179.11%
2016-06-30	AU$5.95 Million ≈ $4.21 Million	AU$-549.72K ≈ $-388.96K	-0.092x	--

About Noxopharm Ltd

AU:NOX Australia Biotechnology

Market Cap

$7.61 Million

AU$10.75 Million AUD

Market Cap Rank

#27575 Global

#1351 in Australia

Share Price

AU$0.04

Change (1 day)

+0.00%

52-Week Range

AU$0.04 - AU$0.10

All Time High

AU$1.58